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Purpose: To screen mitochondrial DNA (mtDNA) variations in Leber hereditary optic neuropathy (LHON).
Methods: Ten LHON patients were selected from neuro-ophthalmology clinics of All India Institute of Medical Sciences
(AIIMS), New Delhi, India. Clinical evaluation included slit-lamp biomicroscopy, fundus examination, and neuroimaging.
DNA was isolated from whole blood samples. The entire coding region of the mitochondrial genome was amplified by
PCR in ten patients and 20 controls. The full mtDNA genome except D-loop was sequenced. All sequences were analyzed
against mitochondrial reference sequence NC_012920.
Results: MtDNA sequencing revealed a total of 30 nucleotide variations in the ten LHON patients and 29 in the 20 controls.
Of 30 changes, 30.00% (9/30) were nonsynonymous, and the remaining 70.00% (21/30) were synonymous. In controls,
a total of five changes were nonsynonymous. Out of the total 14 nonsynonymous changes observed in cases and controls,
four (p.A52T in nicotinamide adenine dinucleotide [NADH] dehydrogenase [ND1] protein; p.L128Q in ND2; p.W48R
in ATPase6; p.R340H in ND4 protein) were pathogenic. Four patients were positive for either of pathogenic changes. In
total, 16.66% (5/30) variations were novel out of which 40.00% (2/5) were nonsynonymous. All novel variations were
submitted to the GenBank database, and accession numbers were obtained. Primary LHON mutations in complex I genes
have been considered a hallmark feature of LHON patients, and primary LHON mutations were present in two cases in
this study. Mutations in complex I genes (ND genes) account for 50%–90% of LHON pedigrees in different ethnic
pedigrees. In this study the highest numbers of changes were also present in complex I genes (46.66%; 14/30) followed
by complex IV (30.00%; 9/30), complex III (16.66%; 5/30), and then complex V (6.66%; 2/30). Complex I had 5/30
(16.66%) nonsynonymous changes, complex III had 1/30 (3.33%), complex IV had 1/30 (3.33%), and complex V had
2/30 (6.66%) nonsynonymous changes. Nonsynonymous mutations in cytochrome c oxidase (COX) genes have been
reported previously in LHON patients. Nonsynonymous mtDNA variations may adversely affect the respiratory chain
and impair the oxidative phosphorylation (OXPHOS) pathway, resulting in low ATP production and elevated reactive
oxygen species (ROS) levels, which cause oxidative stress. It has previously been reported that oxidative stress (OS) leads
to oxidative damage of cellular macromolecules, such as mitochondrial and nuclear DNA, proteins, and lipids along with
energy depletion and a local imbalance of calcium homeostasis, resulting in neuronal degeneration. OS is the underlying
etiology in several ocular diseases and also plays an essential role in LHON.
Conclusions: A total of five novel mtDNA variations were identified in this study. Nonsynonymous mtDNA variations
may adversely affect the respiratory chain and impair the OXPHOS pathway, resulting in low ATP production and elevated
ROS levels. OS further damages both nuclear and mtDNA. This preliminary study describes mtDNA sequence variations
in a relatively small number of LHON patients of north Indian ethnic origin. However, these results should be confirmed
in other populations. Early diagnosis of mtDNA variations and prompt anti-oxidant administration in these cases may
delay OS-induced injury to retinal ganglion cells (RGCs) and hence improve visual prognosis.
Leber  hereditary  optic  neuropathy  (LHON;  OMIM
535000) was first described as a distinctive clinical entity in
1871 by the German ophthalmologist Theodore Leber (1840–
1917) [1]. LHON is a maternally inherited disease leading to
acute bilateral blindness due to loss of the optic nerve and
papillomacular bundle nerve fibers, predominantly in young
men [2]. The prevalence is estimated to be 1:50,000. LHON
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begins generally in young adults, with a mean age of onset
between 18 and 35 years. Nearly all patients worldwide carry
one  of  three  mitochondrial  (mt)  DNA  pathogenic  point
mutations  at  positions  11778/nicotinamide  adenine
dinucleotide (NADH) dehydrogenase (ND)4, 3460/ND1, and
14484/ND6, which affect complex I subunit genes [3]. Other
pathogenic point mutations have also been described in a
minority  of  patients  [4,5].  Although  visual  failure  is  the
defining  feature  in  this  mitochondrial  disorder,  cardiac
arrhythmias, and neurologic abnormalities, such as postural
tremor, peripheral neuropathy, nonspecific myopathy [6], and
movement disorders [7], have also been reported to be more
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782common in LHON patients compared to controls. Pathogenic
mutations in different mitochondrial genes in LHON patients
have  been  reported  in  previous  studies  [8-13].  In  this
preliminary  study  we  investigated  a  series  of  patients
presenting  at  ophthalmology  clinics  with  subacute  visual
failure and who were suspected of having LHON. This study
was planned with the aim to screen LHON cases for mtDNA
sequence variations by PCR–DNA sequencing.
METHODS
Clinical examination and selection of cases: After receiving
ethical  approval  from  the  institutional  review  board
(IRB#00006862;  All  India  Institute  of  Medical  Sciences,
Delhi,  India),  ten  clinically  diagnosed  LHON  cases  from
northern  India,  presenting  at  the  Dr.  R.  P.  Centre  for
Ophthalmic  Sciences  (AIIMS,  New  Delhi,  India),  were
enrolled for this study only after informed consent. LHON
was diagnosed on the basis of a high index of suspicion. Since
it is mainly a diagnosis of exclusion, all other causes were
considered and ruled out. Detailed family history was taken,
including associated peri-ocular pain to differentiate from
papillitis, and the history of chronic tobacco or alcohol or
chronic systemic medication was noted to rule out toxic optic
neuropathy. Family history of any similar episode was noted,
and  the  family  tree  was  charted.  Detailed  systemic  and
neurologic examinations were done to check the involvement
of other cranial and peripheral nerves. Visual field evaluation,
electrophysiological  electro-retinogram,  and  visual-evoked
potential were done in all patients. All patients underwent a
complete  ophthalmic  examination,  including  visual  acuity
measurement, slit-lamp observation of the anterior segment,
indirect ophthalmoscopy, and applanation tonometry. Visual
field testing was performed in all patients with good fixation.
All patients underwent magnetic resonance imaging (MRI) of
the brain and orbit and flourescein angiography.
Hospital  records  were  reviewed,  and  full  neuro-
ophthalmologic examinations were performed on all patients.
The  mean  age  of  onset  of  symptoms  was  24.9  years  (all
patients were male). No patient reported any drastic changes
in their diet or intake of any drug or exposure to any toxic
agent/pollutant around the time of visual loss. All patients had
normal erythrocyte sedimentation rate, antinuclear antibodies,
and syphilis serology. None of the patients reported myotonia,
exercise  intolerance,  palpitations,  cardiac  conduction
abnormalities, oral or genital ulcers, erythema nodosum, or
somatic  anomalies.  Patients  were  followed  in  a  neuro-
ophthalmology clinic. The clinical manifestation of all LHON
patients has been tabulated (Table 1).
A  total  of  20  ethnically  and  age-matched  normal
individuals  without  any  history  of  ocular  disorders  was
enrolled as controls. All control subjects were AIIMS blood
donors who reported no symptomatic metabolic, genetic, or
ocular  disorders  on  an  extensive  questionnaire  regarding
family history, past medical problems, and current health. The
control group for mtDNA sequencing consisted of 20 male
individuals (mean age, 23.85±3.34 years). Family information
was obtained by history.
Sample  collection  and  DNA  isolation:  Peripheral  blood
samples (5 ml, blood drawn by venipuncture) were collected
in EDTA vacutainers (Greiner Bio-one Catalogue no. 455036;
Frickenhausen, Germany) after obtaining written consent and
stored at −80 °C until further use. DNA was extracted from
whole blood samples of all LHON patients and controls, using
the phenol chloroform method [14].
TABLE 1. CLINICAL PHENOTYPES OF LEBER HEREDITARY OPTIC NEUROPATHY PATIENTS
VA Fields
Patient ID Age of onset
(in years)
Sex Neuro-
imaging OD OS Fundus findings OD OS
LHON 1 22 M Normal CF3ft CF5ft diffuse disc pallor Not possible Not possible
LHON 2 25 M Normal 20/80 20/50 diffuse disc pallor central
scotoma
central
scotoma
LHON 3 27 M Normal CF5ft 20/60 diffuse disc pallor Not possible central
scotoma
LHON 4 24 M Normal HMCF LP only diffuse disc pallor Not possible Not possible
LHON 5 29 M Normal 20/100 20/50 Severely diffuse disc
pallor
central
scotoma
central
scotoma
LHON 6 26 M Normal 20/200 20/100 diffuse disc pallor central
scotoma
central
scotoma
LHON 7 28 M Normal CF5ft 20/60 temporal disc pallor Not possible central
scotoma
LHON 8 21 M Normal 20/60 20/60 Severe diffuse disc
pallor
central
scotoma
central cecal
scotoma
LHON 9 23 M Normal 20/200 20/100 diffuse disc pallor central
scotoma
central
scotoma
LHON 10 24 M Normal CF1ft 20/100 diffuse disc pallor Not possible central
scotoma
Abbrevations: OD represents right eye; OS represents left eye; CF represents counting finger; ft represents distance in feet;
HMCF represents hand motions close to face; LP represents light perception; VA represents visual acuity.
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783PCR  amplification  and  sequence  analysis  of  the
mitochondrial DNA coding region: The entire coding region
of the mtDNA was amplified in LHON patients and controls
using 24 pairs of primers (Table 2) [15]. PCR amplifications
for  all  primer  sets  were  performed  in  a  40-μl  volume
containing 1.0 μl of 20 μM stock solution for each primer
(Eurofins Genomics India pvt Ltd, Bangalore, India), 100 ng
of genomic DNA, 1 unit of Taq polymerase (Banglore Genei,
Bengaluru,  Karnataka,  India),  0.1  mM  of  each
deoxynucleotide triphosphate (dNTP), and 4 μl of 10X PCR
buffer  (with  15  mM  MgCl2)  by  means  of  30  cycles  of
amplification, each consisting of 30 s denaturation at 94 °C,
30 s annealing at 56 °C, and 1 min extension at 72 °C. Finally,
an extension for 5 min at 72 °C was performed.
Amplified PCR products were purified using a gel/PCR
DNA fragments extraction kit (Geneaid Biotech Ltd., Sijhih
City,  Taiwan).  Purified  PCR  products  were  sent  for
sequencing to Molecular Cloning Laboratories (South San
Francisco, CA). The full mtDNA genome was sequenced
except D-loop, as this part of the mitochondrial genome is a
hyper-variable region. All fragments were sequenced in both
forward  and  reverse  directions  for  confirmation  of  any
nucleotide variation. All sequence variants from both LHON
patients  and  controls  were  compared  to  the  Human
Mitochondrial Reference Sequence NC_012920 provided by
the National Center for Biotechnology Information (NCBI),
using ClustalW2 (multiple sequence alignment program for
DNA;  European  Bioinformatics  Institute,  Wellcome  Trust
Genome Campus, Hinxton, Cambridge, UK).
Computational  assessment  of  missense  mutations:  Two
homology-based  programs,  Polymorphism  Phenotyping
(PolyPhen)  and  Sorting  Intolerant  From  Tolerant  (SIFT)
analysis tool, were used to predict the functional impact of
missense  changes  identified  in  this  study.  PolyPhen
structurally  analyzes  an  amino  acid  polymorphism  and
predicts  whether  that  amino  acid  change  is  likely  to  be
deleterious to protein function [16,17]. PolyPhen scores of
>2.0  indicate  the  polymorphism  is  probably  damaging  to
protein function. Scores of 1.5–2.0 are possibly damaging,
and scores of <1.5 are likely benign. SIFT is a sequence
homology-based tool that sorts intolerant from tolerant amino
acid  substitutions  and  predicts  whether  an  amino  acid
substitution in a protein will have a phenotypic effect [18].
SIFT  is  based  on  the  premise  that  protein  evolution  is
correlated with protein function. Positions with normalized
probabilities less than 0.05 are predicted to be deleterious and
those greater than or equal to 0.05 are predicted to be tolerated
in the case of SIFT.
The substitution may occur at a specific site, e.g., active
or binding, or in a nonglobular, e.g., transmembrane, region.
PolyPhen uses the predicted hydrophobic and transmembrane
(PHAT) matrix score to evaluate the possible functional effect
of a substitution in the transmembrane region. At this step
Polyphen memorizes all positions that are annotated in the
query protein as BINDING, ACT_SITE, LIPID, or METAL.
At a later stage, if the search for a homologous protein with
known three-dimensional structure is successful, PolyPhen is
checked whether the substitution site is in spatial contact with
these critical residues. Positions important for function should
be conserved in an alignment of the protein family, whereas
unimportant positions should appear diverse in an alignment.
TABLE 2. PRIMERS USED FOR POLYMERASE CHAIN REACTION USED FOR AMPLIFICATION OF MITOCHONDRIAL GENOME.
Name Primer sequence Name Primer sequence
1F.611 CTCCTCAAAGCAATACACTG 13F.8621 TTTCCCCCTCTATTGATCCC
1R.1411 TGCTAAATCCACCTTCGACC 13R.9397 GTGGCCTTGGTATGTGCTTT
2F.1245 CGATCAACCTCACCACCTCT 14F.9230 CCCACCAATCACATGCCTAT
2R.2007 TGGACAACCAGCTATCACCA 14R.10130 TGTAGCCGTTGAGTTGTGGT
3F.1854 GGACTAACCCCTATACCTTCTGC 15F.9989 TCTCCATCTATTGATGAGGGTCT
3R.2669 GGCAGGTCAATTTCACTGGT 15R.10837 AATTAGGCTGTGGGTGGTTG
4F.2499 AAATCTTACCCCGCCTGTTT 16F.10672 GCCATACTAGTCTTTGCCGC
4R.3346 AGGAATGCCATTGCGATTAG 16R.11472 TTGAGAATGAGTGTGAGGCG
5F.3169 TACTTCACAAAGCGCCTTCC 17F.11314 TCACTCTCACTGCCCAAGAA
5R.3961 ATGAAGAATAGGGCGAAGGG 17R.12076 GGAGAATGGGGGATAGGTGT
6F.3796 TGGCTCCTTTAACCTCTCCA 18F.11948 TATCACTCTCCTACTTACAG
6R.4654 AAGGATTATGGATGCGGTTG 18R.12772 AGAAGGTTATAATTCCTACG
7F.4485 ACTAATTAATCCCCTGGCCC 19F.12571 AAACAACCCAGCTCTCCCTAA
7R.5420 CCTGGGGTGGGTTTTGTATG 19R.13507 TCGATGATGTGGTCTTTGGA
8F.5255 CTAACCGGCTTTTTGCCC 20F.13338 ACATCTGTACCCACGCCTTC
8R.6031 ACCTAGAAGGTTGCCTGGCT 20R.14268 AGAGGGGTCAGGGTTGATTC
9F.5855 GAGGCCTAACCCCTGTCTTT 21F.14000 GCATAATTAAACTTTACTTC
9R.6642 ATTCCGAAGCCTGGTAGGAT 21R.14998 AGAATATTGAGGCGCCATTG
10F.6469 CTCTTCGTCTGATCCGTCCT 22F.14856 TGAAACTTCGGCTCACTCCT
10R.7315 AGCGAAGGCTTCTCAAATCA 22R.15978 AGCTTTGGGTGCTAATGGTG
11F.7148 ACGCCAAAATCCATTTCACT 23F.15811 TCATTGGACAAGTAGCATCC
11R.8095 CGGGAATTGCATCTGTTTTT 23R.765 GAGTGGTTAATAGGGTGATAG
12F.7937 ACGAGTACACCGACTACGGC 24F.16420 CACCATTCTCCGTGAAATCA
12R.8797 TGGGTGGTTGGTGTAAATGA 24R.775 AGGCTAAGCGTTTTGAGCTG
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MtDNA  sequencing  revealed  a  total  of  30  nucleotide
variations in the ten LHON patients, of which 30.00% (9/30)
were nonsynonymous (Table 3), and 29 nucleotide changes in
20 controls, of which 17.24% (5/29) were nonsynonymous
(Table  4).  Of  the  30  changes  30.00%  (9/30)  were
nonsynonymous  and  the  remaining  70%  (21/30)  were
synonymous. Of the total changes 96.66% were transitions
and the remaining were transversions. In total, 16.66% (5/30)
variations  were  novel,  out  of  which  40.00%  (2/5)  were
nonsynonymous.  Twenty-five  other  mtDNA  sequence
variations (see the MITOMAP and DB) were also identiﬁed
in patients. The highest number of changes were present in
complex I genes (46.66%; 14/30), followed by complex IV
(30%; 9/30), then complex III (16.66%; 5/30), then complex
V  (6.66%;  2/30)  genes.  Complex  I  had  5/30  (16.66%)
nonsynonymous  changes,  complex  III  had  1/30  (3.33%),
complex  IV  had  1/30  (3.33%),  and  complex  V  had  2/30
(6.66%) nonsynonymous changes. All nucleotide variations
identified in the current study were homoplasmic. All novel
variations  were  submitted  to  the  GenBank  database,  and
accession numbers were obtained (Table 3).
Sorting  Intolerant  From  Tolerant  and  Polymorphism
Phenotyping analysis: SIFT and PolyPhen analysis of all 14
nonsynonymous  changes  (9+5)  from  cases  and  controls
revealed four pathogenic changes (p.A52T in ND1 protein;
p.L128Q in ND2; p.W48R in ATPase6; p.R340H in ND4
protein; Table 3). Four patients (LHON 5–8, Table 5) were
positive for at least one of these pathologic mtDNA nucleotide
changes, but none of the controls harbored any pathogenic
nucleotide  change  (Table  4).  Patient  and  gene-wise
distribution of mtDNA sequence changes have been tabulated
(Table 5).
DISCUSSION
In this preliminary pilot study, we enrolled ten LHON patients
who experienced acute or subacute, bilateral, persistent, optic
neuropathies characterized by central visual loss that occurred
simultaneously or sequentially within a period of 1 year. Leber
described  a  maternal  inheritance  pattern;  however,  some
patients with primary LHON mutations deny having a family
history.
LHON-associated  mtDNA  mutations  have  been
identified in various ethnic populations [19,20]. Mutations in
complex I genes (ND genes) account for 50%–90% of LHON
pedigrees in different ethnic pedigrees [11,13,21,22]. Primary
LHON mutations have been considered a hallmark feature of
LHON  patients,  and  patients  without  primary  LHON
mutations  have  also  been  reported  [23,24].  In  this  study
46.66% variations were reported in complex I (ND group of
genes)  genes,  of  which  three  were  novel  changes.  Three
pathogenic mutations (p.A52T in ND1; p.L128Q in ND2; and
p.R340H in ND4) were present in complex I genes. Primary
LHON  mutation  3460G>A  (p.A52T)  was  present  in  one
patient (LHON 8), 11778G>A (p.R340H) was present in one
patient (LHON 5), and 14484T>C (p.M64V in ND6) was
absent in our patients.
Altered  ubiquinone  binding  to  complex  I  has  been
previously shown in the presence of several LHON-causing
mutations. Decreased affinities for ubiquinone or the complex
I  inhibitor  rotenone  have  been  shown  in  the  3460G>A
(p.A52T)  and  11778G>A  (p.R340H)  mutations  [25-28].
Substrate inhibition at higher concentrations of ubiquinone
has previously been observed in the mitochondrial membrane
preparations from Ebstein-Barr virus-transformed cell lines
carrying the 3460G>A (p.A52T) or 14459G>A (p.A72V in
ND6)  mutations  [25,29].  No  primary  LHON  mutation  or
pathogenic mutation was present in control subjects. The age
of onset symptoms did not differ significantly in patients with
and without pathogenic mutations in the current study.
In the current study two patients (LHON 8 and LHON 5)
had  primary  LHON  mutations  (3460G>A  [p.A52T];
11778G>A [p.R340H]). But none of the patients with primary
LHON  mutations  reported  a  multigenerational  history
compatible with maternal inheritance. Two patients (LHON
6 and LHON 7) had pathogenic mtDNA sequence changes
other than primary LHON mutations, while others had no
suspicious mtDNA changes. Patients with no obvious mtDNA
abnormalities might have no mitochondrial disease or they
might have mtDNA abnormalities isolated to the optic nerve,
conceptually  similar  to  mitochondrial  myopathies  [30].
However, these patients may have elevated oxidative stress
comparable to patients with primary LHON mutations [31].
Previous studies have suggested similar patients with LHON-
like optic neuropathies but no identified pathogenic mtDNA
mutations  after  sequencing  all  [24]  or  part  [32]  of  the
mitochondrial coding region. The phenotypic expression of
the primary LHON mutations is very complex. Only about
one-third  of  individuals  harboring  one  of  these  three
mutations eventually develops LHON, and the penetrance
varies  among  different  families  [33-35].  Therefore,
identification of other factors affecting LHON penetrance
would be of value in elucidating the pathophysiology of retinal
neuron loss as well as in searching for clues that might relieve
visual loss or prevent the onset of LHON. Many factors, such
as  mtDNA  background,  heteroplasmy  of  the  mtDNA
mutation, nuclear gene(s), and environmental factors, have
been shown to play active roles in the phenotypic expression
of LHON [36-38].
In this study one nonsynonymous sequence change and
four synonymous sequences in the cytochrome c oxidase III
(COIII) gene were also identified of which two were novel.
Nonsynonymous  mutations  in  the  COIII  gene  have  been
reported previously in LHON patients [12,39]. Other human
diseases  associated  with  cytochrome  c  oxidase  (COX)
mutations  include  primary  congenital  glaucoma  (PCG),
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788primary open angle glaucoma (POAG), and Leigh syndrome
[15,40,41].
In  this  study  one  patient  (LHON  10)  had  a
nonsynonymous sequence change in cytochrome b (complex
III). Nonsynonymous mutations in the cytochrome b gene has
previously  been  described  in  LHON  [42].  Two
nonsynonymous changes in ATPase6 (p.T53I and p.W48R)
were also identified, one of which (p.W48R) was pathogenic
and present in one patient (LHON 5). ATPase6 mutations in
LHON  patients  have  been  described  previously  [43].
Mutations in ATPase6 have been reported in PCG, POAG,
neuropathy, ataxia, retinitis pigmentosa, and mitochondrial
DNA-associated Leigh Syndrome patients [15,40,44,45]. In
this study eight patients had no primary LHON mutations.
However, two other pathogenic mutations were present in
three patients (Table 5).
An intriguing feature of LHON is that only 50% of males
and 10% of females who harbor one of the three primary
mutations  actually  develop  the  optic  neuropathy.  This
incomplete  penetrance  and  predilection  for  males  to  lose
vision  imply  that  additional  genetic  and/or  environmental
factors must modulate the phenotypic expression of LHON.
No generally accepted measures have been shown to either
prevent or delay the onset of blindness in LHON. The long-
term  management  of  visually  impaired  patients  remains
supportive, with provision of visual aids and registration with
the relevant social services.
Many mechanisms have been studied and proposed as the
bases  for  the  pathogenesis  of  mitochondrial  optic
neuropathies, including bioenergetic failure, oxidative stress,
glutamate  toxicity,  abnormal  mitochondrial  dynamics  and
axonal transport, and susceptibility to apoptosis [3]. It has
been well established that optic atrophy is a very common and
sometimes the singular pathological feature in mitochondrial
disorders [41]. Several human diseases have been associated
with mtDNA mutations, indicating that dysfunction of the
components  of  oxidative  phosphorylation  encoded  by  the
mitochondrial genome can be deleterious [46]. Abnormalities
in mtDNA have proven to be associated with LHON [40],
POAG, pseudoexfoliation glaucoma (PEG), primary angle-
closure glaucoma (PACG), PCG, and other spontaneous optic
neuropathies [15,47-50]. It is generally agreed that there are
two  main  sites  in  the  respiratory  chain  where  superoxide
anions are generated, viz., complex I and complex III [51,
52].  In  the  current  study  complex  I  genes  had  16.66%
nonsynonymous sequence changes, and of these three were
pathogenic mutations.
The distribution of high numbers of mitochondria in the
optic nerve head reflects the high energy requirement of the
human  optic  nerve  head.  Neurons,  because  of  their  high
energy requirement, are heavily dependent on mitochondria
for  survival  [53].  Any  malfunction  of  the  mitochondrial
electron transport chain results in an excessive generation of
free radicals and low ATP production. It has previously been
reported that oxidative stress (OS) leads to oxidative damage
of  cellular  macromolecules,  such  as  mitochondrial  and
nuclear  DNA,  proteins,  and  lipids,  along  with  energy
depletion and a local dysregulation of calcium homeostasis,
resulting in neuronal degeneration [54]. OS is the underlying
etiology in several ocular diseases, such as glaucoma, LHON,
proliferative vitreoretinopathies, and cataract [40,55-57]. It
has been established that pathogenic mitochondrial mutations
can cause mitochondrial dysfunction and enhance OS, which
in turn lead to apoptosis in affected tissue and primary culture
of  human  cells  that  harbor  mtDNA  mutations  [58].
Nonsynonymous  mtDNA  alterations  may  lead  to
mitochondrial  dysfunction,  which  leads  to  reduced
mitochondrial respiration, OS, damage to mtDNA, altered
mitochondrial  morphology,  alterations  in  mitochondrial
fission and fusion, and ultimately the cell’s demise. Oxidative
stress-induced mtDNA damage has also been reported in other
diseases, such as premature ovarian insufficiency [59]. LHON
and LHON-like optic neuropathies might approach 20 per
100,000  individuals  [60],  and  this  diagnosis  may  be
responsible for as much as 10% of blindness in individuals
under age 65 [61].
This study describes mtDNA sequence variations in a
relatively small number of LHON patients of north Indian
ethnic  origin.  Nonsynonymous  mitochondrial  variations
adversely  affect  oxidative  phosphorylation,  resulting  in
decreased mitochondrial respiration and increased free radical
production [62]. However, these results should be confirmed
by larger studies in other populations. Knowledge of mtDNA
mutations and/or mitochondrial dysfunction in LHON may
lead to a better understanding of optic atrophy in LHON.
Novel  approaches  are  now  available  for  studying
mitochondrial disease in the eye, and a novel in vitro treatment
has already been devised for the metabolic defect of at least
one mtDNA mutation in LHON [63]. Further work and ideas
must be forthcoming to realistically treat mtDNA disease or
prevent  the  transmission  of  mtDNA  disease  to  future
generations. Early diagnosis and prompt management by anti-
oxidants may delay the progression of disease.
Conclusion: A total of five novel mtDNA variations were
identified  in  this  study,  of  which  one  was  pathogenic.
Nonsynonymous mtDNA variations may adversely affect the
respiratory chain and impair the OXPHOS pathway, resulting
in low ATP production and elevated ROS levels. OS further
damages both nuclear and mtDNA. This preliminary study
describes mtDNA sequence variations in a relatively small
number  of  LHON  patients  of  north  Indian  ethnic  origin.
However,  these  results  should  be  confirmed  in  other
populations.
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